09:51 AM EST - Oncolytics Biotech Inc : Today announced updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareorep in gastrointestinal cancers. The study is supported in part by a grant from the Pancreatic Cancer Action Network (PanCAN). Oncolytics Biotech Inc
shares N.ONCY are trading unchanged at $1.23.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=5844773132864004
